Abvc Biopharma Stock Performance
| ABVC Stock | USD 2.86 0.14 4.67% |
ABVC Biopharma holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.14, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ABVC Biopharma will likely underperform. Use ABVC Biopharma expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on ABVC Biopharma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ABVC Biopharma are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, ABVC Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (6.25) | Five Day Return 4.17 | Year To Date Return 367.8 | Ten Year Return 423.33 | All Time Return (99.99) |
Last Split Factor 1:10 | Dividend Date 2019-05-08 | Last Split Date 2023-07-25 |
1 | ABVC BioPharma Announces 100 Million Mixed Securities Shelf Filing ABVC Stock News | 05/22/2025 |
2 | Acquisition by Smith J.b. of tradable shares of ABVC Biopharma at 55000.0 subject to Rule 16b-3 | 05/29/2025 |
3 | ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value | 06/03/2025 |
4 | ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma Commits to Up to 20 Million in Total Investment | 06/24/2025 |
5 | Acquisition by Smith J.b. of 192308 shares of ABVC Biopharma at 50000.0 subject to Rule 16b-3 | 06/27/2025 |
6 | ABVC BioPharma Trading 1.7 percent Higher Still a Buy | 07/16/2025 |
7 | ABVC BioPharma Strengthens Oncology Partnership With 100,000 Milestone Payment From OncoX BioPharma | 07/24/2025 |
8 | Why ABVC BioPharma Inc. stock attracts strong analyst attention - Fast Entry High Potential Stock Alerts Triggered - beatles.ru | 07/29/2025 |
| Begin Period Cash Flow | 716.8 K |
ABVC Biopharma Relative Risk vs. Return Landscape
If you would invest 132.00 in ABVC Biopharma on May 8, 2025 and sell it today you would earn a total of 168.00 from holding ABVC Biopharma or generate 127.27% return on investment over 90 days. ABVC Biopharma is currently generating 1.9857% in daily expected returns and assumes 11.4234% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than ABVC, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ABVC Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ABVC Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ABVC Biopharma, and traders can use it to determine the average amount a ABVC Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1738
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ABVC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.42 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.99 actual daily | 40 60% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average ABVC Biopharma is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ABVC Biopharma by adding it to a well-diversified portfolio.
ABVC Biopharma Fundamentals Growth
ABVC Stock prices reflect investors' perceptions of the future prospects and financial health of ABVC Biopharma, and ABVC Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ABVC Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.11 | ||||
| Operating Margin | (5.04) % | ||||
| Current Valuation | 56.29 M | ||||
| Shares Outstanding | 16.98 M | ||||
| Price To Book | 10.05 X | ||||
| Price To Sales | 100.21 X | ||||
| Revenue | 509.59 K | ||||
| Gross Profit | 507.9 K | ||||
| EBITDA | (4.34 M) | ||||
| Net Income | (5.26 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 2.43 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.37 X | ||||
| Cash Flow From Operations | (1.81 M) | ||||
| Earnings Per Share | (0.19) X | ||||
| Market Capitalization | 50.94 M | ||||
| Total Asset | 7.54 M | ||||
| Retained Earnings | (68.95 M) | ||||
| Working Capital | (4.38 M) | ||||
About ABVC Biopharma Performance
By analyzing ABVC Biopharma's fundamental ratios, stakeholders can gain valuable insights into ABVC Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ABVC Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ABVC Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.9 K | 1.4 K | |
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (4.79) | (5.03) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (4.00) | (3.80) |
Things to note about ABVC Biopharma performance evaluation
Checking the ongoing alerts about ABVC Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ABVC Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ABVC Biopharma is way too risky over 90 days horizon | |
| ABVC Biopharma appears to be risky and price may revert if volatility continues | |
| ABVC Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 509.59 K. Net Loss for the year was (5.26 M) with profit before overhead, payroll, taxes, and interest of 507.9 K. | |
| ABVC Biopharma currently holds about 2.99 M in cash with (1.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| ABVC Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Why ABVC BioPharma Inc. stock attracts strong analyst attention - Fast Entry High Potential Stock Alerts Triggered - beatles.ru |
- Analyzing ABVC Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ABVC Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining ABVC Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ABVC Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ABVC Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ABVC Biopharma's stock. These opinions can provide insight into ABVC Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |